Everyone who is invested in AVXL must watch the Roth panel video. I think Missling did well. For me, the most interesting thing was the smirk on his face when the other panelists were discussing bio-markers and in effect saying we don't know the bio-markers yet. Missling went on to say yes we kind of do know the bio-markers. The other guys probably hadn't reviewed any of the Anavex results before they joined the panel.
Well if nothing else, it’s a pretty good bet Merck, Sage and Takeda have heard of Anavex now so we can scratch them off the list of pharmas to nofify. Not to mention another huge indication.
I think the FDA needs remedial training. There have been significant developments in the field they control and their qualifications have expired. There should be more movement in creating space for new understanding and clear renunciation of the old tried and failed paths.
That way BP could get the message to start re-tooling.